Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $37.8 million versus the consensus estimate of $41.04 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.